Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukémia, chlpatá bunka - antineoplastické činidlá - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systémový - imunosupresíva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pľúcna choroba, chronická obštrukcia - drogy obštrukčnej choroby dýchacích ciest, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - drogy obštrukčnej choroby dýchacích ciest, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Unió Europea - eslovac - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastické činidlá - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

astrazeneca ab, Švédsko - rosuvastatín - 31 - hypolipidaemica